Imagine having a digital copy of your liver and heart that doctors can use to test treatments before giving them to you. It works like a flight simulator for your body, predicting how fatty liver disease might progress or affect your heart. This helps doctors catch problems early and tailor your diet or medicine to your specific biology.
Clinicians struggle to predict the progression of fatty liver disease and its deadly cardiovascular complications due to a lack of personalized, multi-organ data. This leads to late detection of cirrhosis and unexpected heart failure during interventions.
A clinical decision support system (CDSS) featuring virtual twins that integrate mechanistic and machine-learning models of the liver, heart, and circulatory systems.
If you are a software provider dealing with the lack of precision in chronic disease tracking — this project developed a virtual twin embedded in a clinical decision support system that provides personalized management for the 25% of the population with fatty liver disease.
If you are a drug developer dealing with unpredictable patient responses in liver trials — this project developed mechanistic and machine-learning models that predict the impact of novel drug treatments on disease progression.
If you are a clinic dealing with high mortality from cardiovascular comorbidities in liver patients — this project developed a liver-heart axis model that predicts per- or post-intervention heart failure.
Based on available project data, no specific pricing or cost model for the end-user is mentioned; the project is funded by an EU contribution of EUR 9,365,095.
The project uses a large distributed patient cohort across 9 countries, suggesting the models are designed for diverse populations and scalable clinical use.
Based on available project data, specific licensing terms are not provided, though the consortium includes 3 SMEs and 3 industrial partners to ensure market readiness.
The technology is delivered as a clinical decision support system (CDSS) designed to provide actionable insights directly to healthcare professionals.
The project period runs from 2024-01-01 to 2027-12-31, indicating that final validated tools will be available toward the end of 2027.
The consortium is heavily weighted toward research and academia with 16 combined university and research partners, but it maintains a strategic industrial presence with 3 SMEs and 3 industrial partners (14% industry ratio). This structure suggests a high-tech R&D focus with a clear path to commercialization via the SME coordinator, Matical Innovation SL, and a broad European reach across 9 countries.
Contact Matical Innovation SL in Spain
Contact us to connect with the ARTEMIS consortium for licensing the liver-heart virtual twin models.
